When it comes to designing clinical trials for rare and ultra-rare diseases, there are greater challenges companies must overcome in comparison to chronic disease studies.
Tag Archive for: Drug development
With an upfront $800 million payment and $325 million in potential milestones, Otsuka Pharmaceutical is acquiring Jnana Therapeutics’ drug discovery platform and rare disease candidate, the companies announced Thursday.
Today’s serving of alphabet noodle soup to the biopharma industry – IRA, JCA, AAV, VC, and PM to list just five – may seem unpalatable, but the bigger picture is enticing. To focus disproportionately on the challenges is an understandable, tactical response, but we feel that the industry is on the cusp of a new era of growth and transformation, and that this should be celebrated.
As organizations focus on finding the most efficient pathways to market and provide patients with rapid access to novel treatments, they face a variety of regulatory hurdles. These challenges are influenced not only by regional regulatory developments but also by a company’s global footprint, the size and capabilities of regulatory teams, resource limitations and the target markets for commercialization.
Third Arc Bio, led by three former Johnson & Johnson executives, is advancing a portfolio of multifunctional antibodies for cancer and inflammatory and immune-mediated diseases.
Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
Big pharmaceutical companies that make personalized blood cancer treatments are working to cut the manufacturing turnaround time by as much as half in coming years, as they try to deliver them sooner in a patient’s disease course.
Swiss biotech company Asceneuron said on Tuesday it had raised $100 million from investors including the controlling shareholder of Wegovy maker Novo Nordisk to fund clinical development of its Alzheimer’s disease drug.
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on Monday, giving the U.S. drugmaker access to an experimental drug for types of inflammatory bowel diseases.